Date post: | 18-Dec-2015 |
Category: |
Documents |
Upload: | mervin-booker |
View: | 215 times |
Download: | 0 times |
Evidence Based Secondary Prevention
Christopher Cannon, M.D.TIMI Study Group
Cardiovascular Division Brigham and Women’s Hospital
Boston, MA
Presenter Disclosure Information
DISCLOSURE INFORMATION:The following relationships exist related to this presentation:
Research grant support from Accumetrics, AstraZeneca, Merck, Merck/Schering-Plough, and Schering-Plough
and has spoken at symposia sponsored by and served on scientific advisory boards for AstraZeneca, Bristol-Myers Squibb, Glaxo Smith Kline, Merck, Pfizer, Sanofi-Aventis, Merck/Schering-Plough, and Schering-Plough
Christopher P. Cannon, MD
2 Phases of ACS Treatment2 Phases of ACS Treatment
Libby P. Circ 2001;104:365,
AcuteAcute Long-term Long-termAcuteAcute Long-term Long-term(<24hrs) (Discharge)
1. ASA2. Clopidogrel3. Heparin/LMWH4. GP IIb/IIIa inhibitors 5. Beta-blockers6. Nitrates7. ACE inhibitors
1. ASA2. Clopidogrel 3. Beta-blockers4. ACE Inhibitors5. Statins6. Risk factor + Lifestyle Δ’s
Two Targets of Therapy in ACS: Two Targets of Therapy in ACS: Culprit + Multiple “Vulnerable” Culprit + Multiple “Vulnerable”
Plaques Plaques
ACS, acute coronary syndrome.Asakura M, et al. J Am Coll Cardiol. 2001;37:1284-1288.
Angiographic & angioscopic images in 58-year-old man with anterior myocardial infarction
Multiple “vulnerable”
plaques detected in non-culprit
segments 10-12
Culprit lesion (#8)detected with
thrombus (red)
Multiple “vulnerable”
plaques detected in non-culprit segments 1-7
1.1. Smoking cessation Smoking cessation 2.2. Achieve optimal weight Achieve optimal weight 3.3. Daily exerciseDaily exercise4.4. AHA Diet AHA Diet 5.5. HTN control BP < 130/85HTN control BP < 130/856.6. Tight control of glucose in DMTight control of glucose in DM7.7. Statin for LDL > 130 mg/dL. Statin for LDL > 130 mg/dL. 8.8. Lipid-lowering LDL>100mg/dL Lipid-lowering LDL>100mg/dL 9.9. A fibrate or niacin if HDL < 40 A fibrate or niacin if HDL < 40
ACC/AHA UA/NSTEMI ACC/AHA UA/NSTEMI Guidelines:Guidelines:UA/NSTEMI 2002
Braunwald E, et al. 2002. Available at: http://www.acc.org
Risk Factor Modification Medical Therapy
1.Aspirin 75 to 325 mg/d
2.Clopidogrel (if ASA not tolerated)
3.ASA + clopidogrel for 9 months
4. -Blocker
5.Statin and diet if LDL >130 mg/dL
6.Lipid-lowering Rx if LDL >100 p diet
7.ACEI if CHF, EF<0.40, HTN, DM
0 5 10 15 20 25 300
1
2
3
4
5Pravastatin 40 mg
Atorvastatin 80 mg
Hazard ratio = 0.72 (CI 0.52,0.99)
P=0.046
Days following randomization
% o
f p
atie
nts
wit
h d
eath
, MI o
r ,r
eho
spit
aliz
atio
n
for
AC
SDeath, MI or ACS Rehospitalization
In First 30 days
KK Ray et al. JACC 2005
CHD Event Rates in Secondary Prevention and ACS Trials
Updated from - O’Keefe, J. et al., J Am Coll Cardiol 2004;43:2142-6.
y = 0.1629x · 4.6776R² = 0.9029p < 0.0001
LDL Cholesterol (mg/dl)
CH
D E
ven
ts (
%)
PROVE-IT-PR
PROVE-IT-AT CARE-S
LIPID-S
HPS-S4S-S
HPS-P
CARE-P
LIPID-P
4S-P
0
5
10
15
20
25
30
30 50 70 90 110 130 150 170 190 210
TNT 80TNT 10A2Z 80
A2Z 20
IDEAL S20/40IDEAL A80
High-dose better High-dose worse
Odds Reduction
Event Rates
No./Total (%)
High Dose Std Dose
-17%147/2099
(7.0)172/2063
(8.3)
-15%205/2265
(9.1)235/2232
(10.5)
-21%334/4995
(6.7)418/5006
(8.3)
-12%411/4439
(9.3)463/4449
(10.4)
-16%1097/13798
(8.0)1288/13750
(9.4)
PROVE IT-TIMI 22
A-to-Z
TNT
IDEAL
Total
0.658451 1 1.51872
OR, 0.8495% CI, 0.77-0.91p=0.00003
Odds Ratio (95% CI)
Meta-Analysis of Intensive Statin Therapy Coronary Death or MI
Cannon CP, et al.Cannon CP, et al. submitted
High-dose statin better High-dose statin worse
Odds Reduction
Event Rates
No./Total (%)
High Dose Std Dose
-16%3972/13798
(28.8)4445/13750
(32.3)
-16%1097/13798
(8.0)1288/13750
(9.4)
-12%462/13798
(3.3)520/13750
(3.8)
+3%340/13798
(2.5)331/13750
(2.4)
-6%808/13798
(5.9)857/13750
(6.2)
-18%316/13798
(2.3)381/13750
(2.8)
Coronary Death or Any Cardiovascular Event
Coronary Death or MI
Cardiovascular Death
Non-Cardiovascular Death
Total Mortality
Stroke
0.5 1 2.5
OR 0.8295% CI, 0.71-0.96p=0.012
Odds Ratio (95% CI)
Meta-Analysis of Intensive Statin Therapy All Endpoints
Cannon CP, et al.
OR, 0.9495% CI, 0.85-1.04P=0.20
OR, 1.0395% CI, 0.88-1.20p=0.73
OR, 0.8895% CI, 0.78-1.00p=.054
OR, 0.8495% CI, 0.77-0.91p=0.00003
OR, 0.8495% CI, 0.80-0.89p<0.0001
Cannon CP, et al. JACC 2006; 48: 438 - 445.
LipidsLipids
““For LDL: For LDL: Lower is Lower is better”better”
Risk Category LDL-C Goal Initiate TLCConsider
Drug Therapy
Very High risk: ACS, or CHD w/ DM,mult CRF
<70 mg/dL 70 mg/dL > 70 mg/dL
High risk: CHD or CHD risk equivalents
(10-year risk >20%)
If LDL <100 mg/dl
<100 mg/dL (optional goal:
<70 mg/dL)
Goal <70 mg/dl
100 mg/dL > 100 mg/dL (<100 mg/dL:
consider drug Rx)
Moderately high risk: 2+ risk factors (10-year risk 10% to 20%)
<100 mg/dL 130 mg/dL > 130 mg/dL (100-129 mg/dL:
consider drug Rx)
Moderate risk: 2+ risk factors ( risk <10%)
<130 mg/dL 130 mg/dL > 160 mg/dL
Lower risk: 0-1 risk factor
<160 mg/dL 160 mg/dL >190 mg/dL
ATP III Update 2004: LDL-C Goals and Cutpoints for Therapy
in Different Risk Categories
Adapted from Grundy, S. et al., Circulation 2004;110:227-39.
Clopidogrel+ ASA
(N=6259)
ASA
(N=6303)
ASA Dose:ASA Dose:
75-100 mg (N=1927)75-100 mg (N=1927) 1.9% 1.9% 3.0% 3.0% 0.53 0.53
100-200 mg (N=7428) 2.8%100-200 mg (N=7428) 2.8% 3.4% 3.4%
200-325 mg (N=2301) 200-325 mg (N=2301) 3.7%3.7% 4.9% 4.9%
Major Bleeding at 1 year by Major Bleeding at 1 year by ASA DoseASA Dose
CURECURE
P-Value
Peters RJG, et al. Circulation 2003;108:1682-1687
Pro
po
rtio
n E
ven
t-F
ree
CURE: Benefit of Clopidogrel Therapy at Over first year
Months
0.90
0.92
0.94
0.96
0.98
1.00
1 4 6 8 10 12
Weeks
Pro
po
rtio
n E
ven
t-F
ree
0.90
0.92
0.94
0.96
0.98
1.00
0 1 2 3 4
RRR 21%RRR 21%95% CI 0.67–0.92 P=0.003
Clopidogrel + ASA
Placebo + ASA
MI, stroke, CV Death: 0–30 days
Yusuf, S. et al for THE CURE Trial Investigators. Circ. 2003;107:966-972.Yusuf, S. et al for THE CURE Trial Investigators. Circ. 2003;107:966-972.
31 days - 1 year
RRR 18%RRR 18%95% CI 0.70–0.95 P=0.009
Clopidogrel + ASA
Placebo + ASA
Benefit of Clopidogrel in PCI Benefit of Clopidogrel in PCI With and Without a StentWith and Without a Stent
Days of Follow upDays of Follow up
PlaceboPlacebo
300300100100 20020000
0.0
0.0
0.02
0.02
0.04
0.04
0.06
0.06
0.08
0.08
0.10
0.10
0.12
0.12
ClopidogrelClopidogrel
RR: 0.73 RR: 0.73 (95% CI 0.56-0.95)(95% CI 0.56-0.95)
p=0.02p=0.02
ClopidogrelClopidogrel
PlaceboPlacebo
RR: 0.56 RR: 0.56 (95% CI 0.34-0.95)(95% CI 0.34-0.95)
P=0.03P=0.03
300300100100 20020000
0.0
0.0
0.05
0.05
0.10
0.10
0.15
0.15
0.20
0.20
Days of Follow upDays of Follow up
CV Death/MI STENT CV Death/MI NO STENT
Mehta SR. ACC 2003
0.14
0.14
CHARISMA: Treatment Effect on Primary and Secondary Endpoints
Bhatt DL, et al. N Engl J Med. 2006;354: Published online.
Cumulative incidence of MI, stroke, CV death; N = 15,603
7% RRRRR 0.93 (0.83–1.05)P=0.22
Months
10
8
6
4
2
00 6 12 18 24 30
PlaceboClopidogrel
Eve
nts
(%
)
20
15
10
5
00 6 12 18 24 30
Months
PlaceboClopidogrel
8% RRRRR 0.92 (0.86-0.995)
Eve
nts
(%
)
P=0.04
Cumulative incidence of MI, stroke, CV death, hospitalization for UA, TIA, revascularization;* N=15,603
*Coronary, cerebral, or peripheral
CHARISMA: Bleeding Endpoints
Event ratenumber of patients (%)
Clopidogrel + ASA
Placebo + ASA P
Severe bleeding
Fatal bleeding
Intracranial hemorrhage
130 (1.7)
26 (0.3)
26 (0.3)
104 (1.3)
17 (0.2)
27 (0.3)
.09
.17
.89
Moderate bleeding 164 (2.1) 101 (1.3) <.001
Bhatt DL, et al. N Engl J Med. 2006;354: Published Online.
GUSTO criteria; N = 15,603
GUSTO = Global Utilization of Streptokinase and t-PA for Occluded Coronary Arteries.
n=3284
n=12,153
N=15,603
CHARISMA: Primary EndpointTreatment Effect by Asymptomatic vs Symptomatic
MI, stroke, CV death
*Multiple atherothrombotic risk factors†Documented coronary, cerebrovascular, or peripheral arterial disease‡P = 0.046
0.5 1.0 1.5Placebobetter
Clopidogrelbetter
Asymptomatic*
Symptomatic†
All patients
Hazard ratio RR (95% CI)
1.20 (0.91–1.59)
0.88 (0.77–0.998)‡
0.93 (0.83–1.05)
Bhatt DL, et al. N Engl J Med. 2006;354:.
Primary Endpoint (MI/Stroke/CV Death) in Patients with Previous MI, IS, or PAD“CAPRIE-like Cohort”
RRR: 17.1 % [95% CI: 4.4%, 28.1%]p=0.01
Pri
mar
y o
utc
om
e ev
ent
rate
(%
)
0
2
4
6
8
10
Months since randomization
0 6 12 18 24 30
Clopidogrel + ASA7.3 %
Placebo + ASA8.8 %
Bhatt DL. Presented at ACC 2006.
N=9478
Nordman AJ, et al. Hot Line Session. World Congress of Cardiology, September 3, 2006, Barcelona.
Incidence of Late Stent Thrombosis: > 1 Year
RR = 5.7
p = 0.049RR = 5.0
p = 0.02
p = 0.22
Per 1,000 pts
0
1
2
3
4
5
6
7
DES/BMS SES/BMS PES/BMSBavry, Kumbhani, Helton, Borek, Mood, Bhatt. AJM 2006. In press
ConclusionsConclusions
• ACS is a manifestation of diffuse ACS is a manifestation of diffuse atherothrombosisatherothrombosis– Multiple plaques, inflammation + Multiple plaques, inflammation +
thrombosisthrombosis
• Long-term medical Rx to prevent events: 5 Long-term medical Rx to prevent events: 5 drugs drugs “ “AtheroAthero + + thrombosisthrombosis””
Statins (high-dose) ASA (low-dose)Statins (high-dose) ASA (low-dose)ACE InhibitorACE Inhibitor Clopidogrel Clopidogrel Beta-blockerBeta-blocker